FY2026 Earnings Estimate for IQVIA Issued By Leerink Partnrs

IQVIA Holdings Inc. (NYSE:IQV) – Research analysts at Leerink Partnrs decreased their FY2026 earnings estimates for shares of IQVIA in a research report issued on Tuesday, November 19th. Leerink Partnrs analyst M. Cherny now anticipates that the medical research company will earn $12.46 per share for the year, down from their previous forecast of $12.49. The consensus estimate for IQVIA’s current full-year earnings is $10.17 per share. Leerink Partnrs also issued estimates for IQVIA’s FY2027 earnings at $13.78 EPS.

Other analysts also recently issued reports about the company. Truist Financial reduced their price target on IQVIA from $286.00 to $265.00 and set a “buy” rating for the company in a research note on Monday, November 4th. Deutsche Bank Aktiengesellschaft decreased their price target on shares of IQVIA from $270.00 to $265.00 and set a “buy” rating on the stock in a research note on Friday, November 1st. BTIG Research dropped their price objective on shares of IQVIA from $290.00 to $260.00 and set a “buy” rating for the company in a research note on Friday, November 1st. The Goldman Sachs Group decreased their target price on shares of IQVIA from $280.00 to $250.00 and set a “buy” rating on the stock in a research report on Friday, November 1st. Finally, Evercore ISI dropped their price target on shares of IQVIA from $270.00 to $265.00 and set an “outperform” rating for the company in a research report on Tuesday, October 8th. Four research analysts have rated the stock with a hold rating, fifteen have assigned a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $256.50.

IQVIA Trading Up 1.6 %

Shares of NYSE:IQV opened at $194.38 on Thursday. IQVIA has a 12-month low of $187.62 and a 12-month high of $261.73. The business has a 50 day moving average of $224.22 and a 200-day moving average of $227.56. The company has a quick ratio of 0.81, a current ratio of 0.81 and a debt-to-equity ratio of 1.76. The stock has a market cap of $35.28 billion, a PE ratio of 25.51, a P/E/G ratio of 1.97 and a beta of 1.51.

Insider Buying and Selling

In related news, insider Eric Sherbet sold 1,300 shares of the firm’s stock in a transaction on Tuesday, August 27th. The stock was sold at an average price of $246.33, for a total transaction of $320,229.00. Following the completion of the transaction, the insider now directly owns 19,536 shares of the company’s stock, valued at $4,812,302.88. This trade represents a 6.24 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. 1.60% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On IQVIA

Several institutional investors and hedge funds have recently made changes to their positions in IQV. PGGM Investments grew its holdings in IQVIA by 55.8% during the 2nd quarter. PGGM Investments now owns 12,073 shares of the medical research company’s stock worth $2,553,000 after acquiring an additional 4,326 shares during the period. Simplify Asset Management Inc. raised its stake in IQVIA by 67.8% during the 3rd quarter. Simplify Asset Management Inc. now owns 9,637 shares of the medical research company’s stock worth $2,284,000 after buying an additional 3,894 shares during the period. Quadrature Capital Ltd bought a new position in IQVIA in the first quarter worth approximately $3,365,000. Raymond James & Associates increased its holdings in shares of IQVIA by 0.7% during the second quarter. Raymond James & Associates now owns 800,374 shares of the medical research company’s stock valued at $169,231,000 after acquiring an additional 5,417 shares in the last quarter. Finally, Versor Investments LP acquired a new position in shares of IQVIA during the third quarter worth approximately $1,328,000. Institutional investors and hedge funds own 89.62% of the company’s stock.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.